AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2875012&ei=kXKaUoDPOcu40AHPMA&usg=AFQjCNFhjbLDC0Zsgq9_kFodjyyOKPEZ_Q
Amgen Inc's Subsidiary Receives U.S. FDA Approval For NEXAVAR (sorafenib)
Friday, 22 Nov 2013 05:30pm EST
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen Inc subsidiary announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. NEXAVAR was approved following a priority review by the FDA, a designation reserved for drugs that may offer a improvement in treatment over existing options.Â 
